🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Rilpivirine (RPV)

Found 88 matching trials

'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

N/A

Dolutegravir (DTG) is a well-tolerated 2nd generation integrase strand tran...

Status

Completed

Location

GSK Investigational Site

Start Date

2019-11-18

Trial ID

NCT04019873

Treatments Being Tested

Dolutegravir (DTG)Lamivudine (3TC)Rilpivirine (RPV)

DRV/r + RPV QD: Efficacy and Toxicity Reduction

PHASE3

Clinical approach to HIV infection treatment is based on the use of highly ...

Status

Completed

Location

Clinica delle Malattie Infettive, Policlinico Universitario

Start Date

2014-09-30

Trial ID

NCT01792570

Treatments Being Tested

RPV + DRV/r continue the PI/r-containing HAART.

Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.

N/A

The RELATIVITY study is a nationwide, multicenter, ambispective observation...

Status

Active Not Recruiting

Location

Hospital Universitario de Burgos

Start Date

2024-12-31

Trial ID

NCT07703748

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

PHASE3

The primary objective of this study is to evaluate the efficacy of switchin...

Status

Completed

Location

University of Alabama at Birmingham

Start Date

2018-08-28

Trial ID

NCT03631732

Treatments Being Tested

B/F/TAF NRTIs Third Agent

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

PHASE3

This Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLA...

Status

Active Not Recruiting

Location

GSK Investigational Site

Start Date

2017-10-27

Trial ID

NCT03299049

Treatments Being Tested

Cabotegravir Tablets Rilpivirine Tablets Cabotegravir Injectable Suspension Rilpivirine Injectable Suspension

Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA)

PHASE4

The purpose of this pharmacokinetic (PK) trial is to evaluate whether the E...

Status

Withdrawn

Location

Multiple Locations

Start Date

2024-01-01

Trial ID

NCT05156658

Treatments Being Tested

Etonogestrel (ENG) Subdermal Implants

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

PHASE3

The primary objective of this study is to evaluate the non-inferiority of s...

Status

Completed

Location

Maricopa Integrated Health System

Start Date

2015-01-26

Trial ID

NCT02345226

Treatments Being Tested

FTC/RPV/TAF EFV/FTC/TDF Placebo EFV/FTC/TDF FTC/RPV/TAF Placebo

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

PHASE1

Treatment of human immunodeficiency virus (HIV) infection requires daily or...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-02

Trial ID

NCT02373930

Treatments Being Tested

DTG 50 mg RPV 25 mg DTG/RPV 50 mg/25 mg: Product Code AS DTG/RPV 50 mg/25 mg: Product Code AM DTG/RPV 50 mg/25 mg: Product Code AQ DTG/RPV 50 mg/25 mg: Product Code AK DTG/RPV 50 mg/25 mg: Product Code AR

Long-Acting Treatment in Adolescents (LATA)

PHASE3

The LATA trial will find out if taking a long-acting injectable form of HIV...

Status

Unknown

Location

Moi University

Start Date

2023-06-22

Trial ID

NCT05154747

Treatments Being Tested

Cabotegravir, Rilpivirine Drug Combination TLD

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

PHASE2

This study is a Phase IIb, randomized, multicentre, parallel group, open-la...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-04-28

Trial ID

NCT02120352

Treatments Being Tested

CAB Oral Tablets CAB LA ABC/3TC Oral tablets RPV Oral Tablets HAART RPV

Previous Next